Comment from Frakes Kyle

Summary: Kyle Frakes, Founder of Moonlight Longevity, supports the inclusion of MOTS-c on the Section 503A Bulk Drug Substances List. He argues that MOTS-c is a safe, mitochondria-derived peptide with significant therapeutic potential for treating metabolic diseases and age-related metabolic decline.